This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Aug;67(2):427-428.

doi: 10.1016/j.jhep.2017.02.035. Epub 2017 Apr 21.

Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment

Sofie Hallager¹, Steen Ladelund², Nina Weis³

Affiliations

Affiliations

¹ Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark. Electronic address: sofie.hallager.02@regionh.dk.
² Clinical Research Center, Copenhagen University Hospital, Hvidovre, Denmark.
³ Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

PMID: 28435039
DOI: 10.1016/j.jhep.2017.02.035

Comment

Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment

Sofie Hallager et al. J Hepatol. 2017 Aug.

. 2017 Aug;67(2):427-428.

doi: 10.1016/j.jhep.2017.02.035. Epub 2017 Apr 21.

Authors

Sofie Hallager¹, Steen Ladelund², Nina Weis³

Affiliations

¹ Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark. Electronic address: sofie.hallager.02@regionh.dk.
² Clinical Research Center, Copenhagen University Hospital, Hvidovre, Denmark.
³ Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

PMID: 28435039
DOI: 10.1016/j.jhep.2017.02.035

No abstract available

PubMed Disclaimer

Comment in

Reply to: "Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment".
Bruno S, Maisonneuve P. Bruno S, et al. J Hepatol. 2017 Aug;67(2):428-429. doi: 10.1016/j.jhep.2017.04.005. Epub 2017 Apr 21. J Hepatol. 2017. PMID: 28435040 No abstract available.

Comment on

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Bruno S, et al. J Hepatol. 2016 Jun;64(6):1217-23. doi: 10.1016/j.jhep.2016.01.034. Epub 2016 Apr 5. J Hepatol. 2016. PMID: 27059129

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations